Non-Invasive Prenatal Testing (NIPT) Market Size, Share, Trends, Industry Analysis Report: By Gestation Period (0-12 Weeks, 13-24 Weeks, and 25-36 Weeks), Component, Method, Application, End Use, and Region (North America, Europe, Asia Pacific, Latin Amer

Non-Invasive Prenatal Testing (NIPT) Market Size, Share, Trends, Industry Analysis Report: By Gestation Period (0-12 Weeks, 13-24 Weeks, and 25-36 Weeks), Component, Method, Application, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) – Market Forecast, 2025–2034

The non-invasive prenatal testing market size is expected to reach USD 11.39 billion by 2034, according to a new study by Polaris Market Research. The report “Non-Invasive Prenatal Testing (NIPT) Market Size, Share, Trends, Industry Analysis Report: By Gestation Period (0-12 Weeks, 13-24 Weeks, and 25-36 Weeks), Component, Method, Application, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Non-invasive prenatal testing (NIPT) refers to a method used to screen for certain genetic conditions in a fetus, such as Down syndrome, using a blood sample from the pregnant individual. This test analyzes small fragments of fetal DNA that are circulating in the maternal blood. It is a preferred option among users for its accuracy and safety compared to invasive methods.

The growing importance of early detection of genetic disorders is a primary driver for the NIPT market. Significant advancements in genomic technology and bioinformatics have propelled the NIPT market. Improvements in next-generation sequencing (NGS) technology have enhanced the accuracy and efficiency of fetal DNA analysis. These technological innovations have led to more affordable and accessible NIPT options, thereby expanding its adoption among healthcare providers and patients. For instance, in May 2021, Illumina, Inc. and Next Generation Genomic Co., Ltd. announced the launch of VeriSeq NIPT Solution v2, a CE-IVD, NGS-based approach to NIPT. As technology continues to evolve, it is expected to improve the capabilities and affordability of NIPT further.

The non-invasive prenatal testing market is driven by intense competition with strategies including price competitiveness and technological innovation with strategic partnerships. For instance, in July 2021, Pacific Biosciences of California, Inc. announced the acquisition of Omniome. With the acquisition, Pacific Biosciences will be able to expand the market opportunity for sequencing in creative ways that benefit customers. Through its innovative methodology, Omniome aims to provide an accurate short-read sequencing platform to enable it to enter rapidly expanding clinical application areas such as non-invasive prenatal testing and oncology.

Additionaly, in October 2024, Yourgene Health installed the first non-invasive prenatal testing (NIPT) workflow in Colombia at Genetix. The service will deliver fast, precise NIPT results for expectant parents in Colombia, serving to reduce turnaround times and delivery problems.

Non-Invasive Prenatal Testing (NIPT) Market Report Highlights

By method analysis, the cell-free DNA in maternal plasma tests segment dominated the market in 2024, mainly attributed to its minimal risk and superior accuracy compared to traditional invasive methods.

By application analysis, the trisomy segment dominated the market in 2024 owing to NIPT's role in detecting common chromosomal abnormalities such as Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome).

North America dominated the market in 2024 due to advanced healthcare infrastructure, high awareness levels, and robust adoption of advanced technologies.

Asia Pacific is expected to register the fastest CAGR, owing to economic growth, technological innovation, geographic expansion, and strategic partnerships.

The key market players include Agilent Technologies, Inc.; Centogene N.V.; Eurofins LifeCodexx GmbH; F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics); Illumina, Inc.; Laboratory Corp. of America Holdings; MedGenome Labs Ltd.; Myriad Women’s Health, Inc.; Natera, Inc.; Progenity, Inc.; Qiagen; Quest Diagnostics, Inc.; and Thermo Fisher Scientific, Inc.

Polaris Market Research has segmented the non-invasive prenatal testing market report based on gestation period, component, method, application, end use, and region:

By Gestation Period Outlook (Revenue – USD Billion, 2020–2034)
0-12 weeks
13-24 weeks

25-36 weeks

By Component Outlook (Revenue – USD Billion, 2020–2034)

Consumables

Instruments

Software

Services

By Method Outlook (Revenue – USD Billion, 2020–2034)

Cell-Free DNA in Maternal Plasma Tests

Ultrasound Detection

Biochemical Screening Tests

Others

By Application Outlook (Revenue – USD Billion, 2020–2034)

Monosomy

Trisomy

Microdeletion Syndrome

Others

By End-Use Outlook (Revenue – USD Billion, 2020–2034)

Diagnostic Centers

Hospitals and Clinics

Others

By Regional Outlook (Revenue – USD Billion, 2020–2034)

North America

• US
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Australia
• Malaysia
• Vietnam
• Rest of Asia Pacific

Latin America

• Argentina
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of the Middle East & Africa